The Federal Trade Commission challenges patents on 20 brand-name drugs to spur competition, including the blockbuster weight-loss drug Ozempic. The FTC sent warning letters to 10 drugmakers alleging certain patents are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and block cheaper generics. FTC Chair Lina Khan said drug companies use "bogus patent listings" to inflate drug prices. This follows a similar FTC action last September challenging over 100 drugmaker patents.
